Meditati is a preclinical stage company dedicated to solving addiction. Our polypharmacology foundation model designs small molecule drugs targeting the underlying neurobiology of mental health disorders. Our lead program, MED-01, has two compounds with in vivo efficacy in a fentanyl addiction model and is positioned to be a first-in-class non-agonist therapy for the treatment of opioid use disorder.